Q1 Earnings Estimate for WVE Issued By HC Wainwright

Wave Life Sciences Ltd. (NASDAQ:WVE) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Wave Life Sciences in a research note issued to investors on Wednesday, March 5th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.15) EPS.

A number of other research firms have also weighed in on WVE. StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. Mizuho increased their price objective on Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Truist Financial boosted their target price on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Finally, Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

Wave Life Sciences Trading Down 5.9 %

Wave Life Sciences stock opened at $10.57 on Thursday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -9.52 and a beta of -1.09. The firm has a 50 day simple moving average of $11.58 and a 200 day simple moving average of $11.19. Wave Life Sciences has a 1-year low of $4.25 and a 1-year high of $16.74.

Hedge Funds Weigh In On Wave Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after acquiring an additional 856 shares in the last quarter. US Bancorp DE boosted its stake in shares of Wave Life Sciences by 53.9% during the 3rd quarter. US Bancorp DE now owns 18,043 shares of the company’s stock valued at $148,000 after purchasing an additional 6,316 shares in the last quarter. Privium Fund Management B.V. purchased a new position in shares of Wave Life Sciences during the third quarter valued at about $400,000. GSA Capital Partners LLP raised its stake in Wave Life Sciences by 14.9% in the third quarter. GSA Capital Partners LLP now owns 63,513 shares of the company’s stock worth $521,000 after buying an additional 8,255 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Wave Life Sciences in the third quarter worth about $194,000. 89.73% of the stock is owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.